Wei Xu1, Yang Gong1, Meng Kuang2, Peng Wu1, Chunxiang Cao3, Jinfei Chen4, Cuiju Tang5. 1. Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, People's Republic of China. 2. Department of Oncology, Liyang People's Hospital, Liyang, Jiangsu, People's Republic of China. 3. Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. 4. Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, People's Republic of China. jinfeichen@sohu.com. 5. Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, People's Republic of China. tangcuiju2016@163.com.
Abstract
BACKGROUND: Recently, the need for maintenance chemotherapy arose as a result of the significantly improved survival of patients with metastatic colorectal cancer (mCRC) without increasing adverse events. Currently used maintenance regimens are fluoropyrimidines, bevacizumab, and the combination of fluoropyrimidine with bevacizumab. A new combination with bevacizumab and erlotinib, a tyrosine kinase inhibitor of the epithelial growth factor receptor, has shown synergistic effects in preclinical tests and promising results in some clinical trials. Whether bevacizumab combined with erlotinib vs. bevacizumab alone as maintenance therapy will further improve the clinical outcomes in patients with mCRC is controversial. We conducted this meta-analysis to compare the survival benefit and safety of these two regimens in patients with mCRC. METHODS: We searched PubMed, EMBASE, and the Central Registry of Controlled Trials of the Cochrane Library up to August 2016. We also searched the Proceedings of the American Society of Clinical Oncology (1986 to August 2016). Abstracts were manually searched to identify relevant trials. A total of three randomized controlled trials with 682 patients met the inclusion criteria. RESULTS: Our results demonstrated that bevacizumab combined with erlotinib significantly improved overall survival (hazard ratio 0.78; 95 % confidence interval 0.66-0.93; p = 0.006) and progression-free survival (hazard ratio 0.79; 95 % confidence interval 0.68-0.92; p = 0.002). Significantly more grade 3 rash, diarrhea, infection total, and fatigue were observed in the bevacizumab combined with erlotinib arm, which were controllable and reversible. CONCLUSIONS: Based on current evidence, the addition of erlotinib to bevacizumab as maintenance therapy significantly increases overall survival and progression-free survival with an increased but manageable toxicity in patients with mCRC. It should be considered as a treatment option for these patients under the premise of a reasonable selection of the target population.
BACKGROUND: Recently, the need for maintenance chemotherapy arose as a result of the significantly improved survival of patients with metastatic colorectal cancer (mCRC) without increasing adverse events. Currently used maintenance regimens are fluoropyrimidines, bevacizumab, and the combination of fluoropyrimidine with bevacizumab. A new combination with bevacizumab and erlotinib, a tyrosine kinase inhibitor of the epithelial growth factor receptor, has shown synergistic effects in preclinical tests and promising results in some clinical trials. Whether bevacizumab combined with erlotinib vs. bevacizumab alone as maintenance therapy will further improve the clinical outcomes in patients with mCRC is controversial. We conducted this meta-analysis to compare the survival benefit and safety of these two regimens in patients with mCRC. METHODS: We searched PubMed, EMBASE, and the Central Registry of Controlled Trials of the Cochrane Library up to August 2016. We also searched the Proceedings of the American Society of Clinical Oncology (1986 to August 2016). Abstracts were manually searched to identify relevant trials. A total of three randomized controlled trials with 682 patients met the inclusion criteria. RESULTS: Our results demonstrated that bevacizumab combined with erlotinib significantly improved overall survival (hazard ratio 0.78; 95 % confidence interval 0.66-0.93; p = 0.006) and progression-free survival (hazard ratio 0.79; 95 % confidence interval 0.68-0.92; p = 0.002). Significantly more grade 3 rash, diarrhea, infection total, and fatigue were observed in the bevacizumab combined with erlotinib arm, which were controllable and reversible. CONCLUSIONS: Based on current evidence, the addition of erlotinib to bevacizumab as maintenance therapy significantly increases overall survival and progression-free survival with an increased but manageable toxicity in patients with mCRC. It should be considered as a treatment option for these patients under the premise of a reasonable selection of the target population.
Authors: Jeffrey A Meyerhardt; Andrew X Zhu; Peter C Enzinger; David P Ryan; Jeffrey W Clark; Matthew H Kulke; Craig C Earle; Michele Vincitore; Ann Michelini; Susan Sheehan; Charles S Fuchs Journal: J Clin Oncol Date: 2006-04-20 Impact factor: 44.544
Authors: Jaafar Bennouna; Javier Sastre; Dirk Arnold; Pia Österlund; Richard Greil; Eric Van Cutsem; Roger von Moos; Jose Maria Viéitez; Olivier Bouché; Christophe Borg; Claus-Christoph Steffens; Vicente Alonso-Orduña; Christoph Schlichting; Irmarie Reyes-Rivera; Belguendouz Bendahmane; Thierry André; Stefan Kubicka Journal: Lancet Oncol Date: 2012-11-16 Impact factor: 41.316
Authors: Lieke H J Simkens; Harm van Tinteren; Anne May; Albert J ten Tije; Geert-Jan M Creemers; Olaf J L Loosveld; Felix E de Jongh; Frans L G Erdkamp; Zoran Erjavec; Adelheid M E van der Torren; Jolien Tol; Hans J J Braun; Peter Nieboer; Jacobus J M van der Hoeven; Janny G Haasjes; Rob L H Jansen; Jaap Wals; Annemieke Cats; Veerle A Derleyn; Aafke H Honkoop; Linda Mol; Cornelis J A Punt; Miriam Koopman Journal: Lancet Date: 2015-04-07 Impact factor: 79.321
Authors: D Koeberle; D C Betticher; R von Moos; D Dietrich; P Brauchli; D Baertschi; K Matter; R Winterhalder; M Borner; S Anchisi; P Moosmann; A Kollar; P Saletti; A Roth; M Frueh; M Kueng; R A Popescu; S Schacher; V Hess; R Herrmann Journal: Ann Oncol Date: 2015-01-20 Impact factor: 32.976
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: A Johnsson; H Hagman; J-E Frödin; A Berglund; N Keldsen; E Fernebro; J Sundberg; R De Pont Christensen; K-L Garm Spindler; D Bergström; A Jakobsen Journal: Ann Oncol Date: 2013-06-19 Impact factor: 32.976
Authors: Karl John Habashy; Rana Mansour; Charbel Moussalem; Raymond Sawaya; Michel J Massaad Journal: Br J Cancer Date: 2022-06-04 Impact factor: 9.075